GET DAILY SIGNALSONMD vs ONMDW: Weighing OneMedNet's Common Stock Against Its Warrants
Key Takeaways
- Two different instruments, one company: ONMD is OneMedNet Corporation's common stock, while ONMDW is a derivative warrant tied to the same underlying business.
- Distinct risk profiles: The common stock reflects the operating company directly, whereas the warrant adds leverage, time-decay, and exercise-price sensitivity on top of business fundamentals.
- Strong bookings momentum: OneMedNet reported roughly $16.2 million in year-to-date bookings, a 16X increase versus the prior-year period, alongside a recent seven-figure multiyear agreement.
- Recent corporate action: A 1-for-10 reverse stock split of ONMD took effect in late September 2026, resetting the common stock's share price and share count.
- Liquidity contrast: ONMD trades with materially higher volume than ONMDW, which is a thinly traded, low-priced warrant with a wide range between its high and low.
- Unprofitable fundamentals: Both instruments ultimately depend on a company that remains loss-making, so relative positioning hinges on growth catalysts versus near-term financial risk.
Two Securities Tied to the Same Business
Investors comparing ONMD and ONMDW are looking at two securities from the same issuer but with very different roles in a portfolio. ONMD represents the common stock of OneMedNet Corporation, a healthcare data and software provider, while ONMDW is a redeemable warrant that gives the holder the right to buy common stock at a set exercise price. This comparison matters for traders evaluating relative performance and for investors deciding between direct equity ownership and a more leveraged, derivative exposure to the same underlying company.
ONMD: The Common Stock View
OneMedNet Corporation (ONMD) operates the iRWD platform, which curates regulatory-grade, de-identified real-world data from medical imaging and clinical records for life sciences, medical device, and artificial intelligence customers. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Recent commercial traction includes a seven-figure multiyear agreement for multimodal clinical data with an AI-enabled precision medicine firm. A 1-for-10 reverse stock split took effect in late September 2026, which adjusted the share count and lifted the nominal price. ONMD has traded well below its 52-week high amid ongoing losses, even as bookings growth has outpaced recognized revenue.
ONMDW: The Warrant Perspective
ONMDW is the public warrant of OneMedNet Corporation, a derivative that allows the holder to purchase one share of common stock at a fixed exercise price. These warrants originated from the company’s 2023 SPAC business combination, after which the stock and warrants began trading separately on Nasdaq. The warrant does not confer direct ownership or voting rights until exercised. In recent trading, ONMDW has stayed at a low price level with thin daily volume, well below the exercise price, and the reverse split triggered standard anti-dilution adjustments to its terms.
Head-to-Head Comparison
The main difference between ONMD and ONMDW is structural. Both ultimately depend on OneMedNet’s ability to turn its growing bookings backlog into revenue and, eventually, profitability. The common stock provides a direct claim on the business with a simpler risk profile, while the warrant introduces embedded leverage, a specific exercise price, and greater sensitivity to time decay. ONMD has shown stronger trading activity and clearer price responses to announcements, whereas ONMDW’s limited liquidity produces sharper but less predictable moves. Both share the same growth drivers, such as rising demand for AI-related healthcare data, yet only the common stock delivers near one-for-one equity participation.
AI Framework Assessment
From what I see, observable factors such as trend consistency, liquidity, stability, and relative positioning suggest Tickeron’s AI framework would lean toward ONMD over ONMDW right now. The common stock delivers more consistent price behavior, higher trading volume, and a direct link to the company’s improving bookings trajectory. The warrant offers greater theoretical upside if the stock rises sharply, but its low liquidity and position well below the exercise price add extra uncertainty. A probabilistic view therefore favors the common stock as the more stable choice, though the warrant’s leverage could suit investors with a higher risk tolerance.
Using Tickeron’s Trending AI Robots for Strategy Ideas
In my own research process, I often review Tickeron’s Trending AI Robots to see which automated strategies are currently aligned with market conditions. The platform highlights a selection of AI-powered bots that trade thousands of tickers, each with its own style, timeframe, and performance history. This helps me cross-check ideas on names like ONMD without replacing my own analysis of fundamentals and liquidity.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Experienced trader focused on market analysis, identifying trading opportunities, and developing custom trading signals based on market trends, price action, and data-driven insights. Join my Trader Club to follow my latest analysis, trading ideas, and active signals: https://tickeron.com/app/trader-club/103/view?tab=active§ion=trades&via=john
ONMD in upward trend: price may ascend as a result of having broken its lower Bollinger Band on September 29, 2026
ONMD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 19 of 21 cases where ONMD's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ONMD's RSI Oscillator exited the oversold zone, 17 of 19 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.
The Moving Average Convergence Divergence (MACD) for ONMD just turned positive on October 21, 2026. Looking at past instances where ONMD's MACD turned positive, the stock continued to rise in 30 of 58 cases over the following month. The odds of a continued upward trend are 52%.
Following a +4.66% 3-day Advance, the price is estimated to grow further. Considering data from situations where ONMD advanced for three days, in 113 of 149 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 19 of 48 cases where ONMD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 40%.
The Momentum Indicator moved below the 0 level on October 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ONMD as a result. In 45 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 55%.
ONMD moved below its 50-day moving average on September 25, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ONMD crossed bearishly below the 50-day moving average on September 29, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 6 of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 60%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ONMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for ONMD entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ONMD's P/B Ratio (-75.161) is very low in comparison to the industry average of (4.622). P/E Ratio (-2.624) is within average values for comparable stocks, (12.887). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.012) among similar stocks. ONMD's P/S Ratio (23.529) is slightly higher than the industry average of (6.065).
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. ONMD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ONMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ServicestotheHealthIndustry
Advertisement